News

Article

Azalea Vision announces first on-eye test of its smart contact lens prototype

Author(s):

According to the company, the device is designed to offer a non-surgical solution for patients suffering from keratoconus, corneal irregularities, photophobia, and presbyopia.

(Image Credit: AdobeStock/Africa Studio)

(Image Credit: AdobeStock/Africa Studio)

Azalea Vision announced the demonstration of its ALMA Lens, the first functional prototype of the Azalea smart contact lens platform.

According to the company, the device is designed to offer a non-surgical solution for patients suffering from keratoconus, corneal irregularities, photophobia, and presbyopia.1

“This test marks a pivotal moment in the pursuit of non-invasive treatment options for challenging ophthalmological conditions,” said Andrés Vásquez Quintero, co-founder and CTO of Azalea vision, who also wore the device.

The company also noted in its release the lens includes an embedded diaphragm, the aperture of which can be modulated to filter the amount of light that enters the eye. The design integrates liquid-crystal technology, a microchip, an RF antenna, a medical-grade micro-battery, and a configurable light control.1

Moreover, the company explained this smart lens is designed to be easy to use and program, by patients and physicians, allowing for personalized therapy and it is designed to significantly enhance visual acuity without the need of surgery.

Azalea noted in the release its first application will focus on helping patients with irregular astigmatism due to keratoconus and other corneal irregularities. By filtering out peripheral light, the smart lens is designed to allow only focused light to reach the retina.

This first application could offer treatment for nearly half a million patients in the EU and USA alone, representing a total addressable market of more than 2 billion euros per year, as it is a renewable market. Neither glasses nor contact lenses currently available on the market can fully resolve the severe visual distortions that Azalea Vision’s ALMA Lens is designed to address.1

Rudy Nuijts, MMA, professor of Medicine and Ophthalmology at University Eye Clinic Maastrich, was pleased to learn of the results.

“In our hospital we treat a lot of patients with severe irregular astigmatism. Patients with corneal irregularities could profit from a non-surgical solution that is designed to filter the aberrated light to recuperate their visual acuity and visual quality,” he said in the news release.

The lens also could benefit patients diagnosed with presbyopia, as its small aperture optics principle could increase patients’ depth of focus and correct refractive errors. The technology could also aid patients with iris disorders, severe light sensitivity due to chronic migraine or dry eye syndrome, as it is designed to diminish the amount of light reaching their eyes.

Enrique Vega, CEO of Azalea Vision, said the success of the company’s prototype highlights his team’s spirit of innovation.

“We’re not just developing a new product category in the medical device sector; we’re pioneering a platform with diverse and groundbreaking applications,” he concluded in the news release.

Based in Belgiulm and founded in July 2021, Azalea Vision is a spin-off from imec and Ghent University and has received support from VLAIO, as well as from MedTech and DeepTech investors that include imec.xpand, Elaia Partners, Sensinnovat, and Shigeru.

Reference:
  1. Azalea Vision announces first on-eye test of alma, its revolutionary Smart Contact Lens, Azalea Vision. Available at: https://azaleavision.com/alma-lens-the-revolutionary-smart-contactlens-by-azalea-vision-promises-new-hope-forpatients-with-vision-disorders. Published December 5, 2023. Accessed December 5, 2023.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.